{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.3","value":"7.2"},{"groupId":"OG001","spread":"9.0","value":"5.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"title":"Stayed in hospital for any health issue including MM"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.2","value":"10.3"},{"groupId":"OG001","spread":"10.3","value":"6.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"Stayed in hospital due to MM"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.6","value":"5.0"},{"groupId":"OG001","spread":"0.5","value":"1.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Stayed in ICU for any health issue including MM"},{"categories":[{"measurements":[{"groupId":"OG001","spread":"2.0","value":"3.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Stayed in ICU due to MM"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"Healthcare utilization at baseline before study medication administration was collected via HRUPQ. The mean number of nights in the past 6 month a participant stayed in hospital for any health issue including MM or due to MM and stayed in intensive care unit (ICU) for any health issue including MM or due to MM is presented. The baseline value was defined as the last non-missing value collected on or before the start date of study medication.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received isatuximab 10 mg/kg IV infusion QW (i.e. on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 10 mg/kg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG000","title":"Isa-IV + Pd"},{"description":"Participants received isatuximab 1400 mg SC injection administered via an OBDS which is an investigational device injector QW (i.e on Days 1, 8, 15 and 22) in Cycle 1 (28 days) and then 1400 mg Q2W (i.e. on Days 1 and 15) of each subsequent 28-day cycle along with pomalidomide 4 mg orally on Days 1 to 21 of each 28-day cycle and dexamethasone 40 mg (or 20 mg for participant \\>=75 years) orally on Days 1, 8, 15, and 22 of each cycle until disease progression, unacceptable AEs, participant request to discontinue treatment, or any other reason, whichever came first.","id":"OG001","title":"Isa-SC + Pd"}],"paramType":"MEAN","populationDescription":"The ITT population included all randomized population. Only those participants with responses at Baseline are presented.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1 Day 1)","title":"HRUPQ: Baseline Healthcare Utilization: Number of Nights in the Past 6 Months a Participant Stayed in Hospital","type":"SECONDARY","unitOfMeasure":"number of nights"}